Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.
Schematic image of naptumomab estafenatox.
: variable (antigen binding) domains of antibody fragment
: constant domains of antibody fragment
: superantigen SEA/E-120
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox"). The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.
- ^ Borghaei, H; Alpaugh, K; Hedlund, G; Forsberg, G; Langer, C; Rogatko, A; Hawkins, R; Dueland, S; Lassen, U (2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of Clinical Oncology. 27 (25): 4116–23. PMC 2734423 . PMID 19636016. doi:10.1200/JCO.2008.20.2515.
- ^ ClinicalTrials.gov
- ^ WHO Drug Information